Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276443 | 0.90 | L3MBTL1 (0.49) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL2276520 | 0.88 | L3MBTL1 (0.47) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL18113578 | 0.87 | L3MBTL1 (0.47) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL13854970 | 0.85 | L3MBTL1 (0.53) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL2274062 | 0.84 | KIT (0.34) | CNR2ACHECNR1 | |
| SCHEMBL2277656 | 0.84 | L3MBTL1 (0.50) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL2468284 | 0.83 | L3MBTL1 (0.49) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL12374208 | 0.83 | L3MBTL1 (0.60) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL173456 | 0.81 | L3MBTL1 (0.57) | L3MBTL1CNR2ACHECNR1MEN1 | |
| SCHEMBL17146107 | 0.81 | MAPK1 (0.33) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| CN-102015693-B | Compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| CN-102015693-A | Compounds as ERK inhibitors | SCHERING CORP | 2011-04-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | L3MBTL1 3012/4885CNR2 3669/4885ACHE 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.